Jean-Louis H. Kerkhoffs

Jean-Louis H. Kerkhoffs

Auto-generated profile, based on publicly available information

Jean-Louis H. Kerkhoffs

Department of Hematology HagaZiekenhuis The Hague the Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2018 in Blood
Verified
Journal Article
Closed access
PDF file
PMPieter F. van der Meer
Pieter F. van der Meer
PYPaula F. Ypma
Paula F. Ypma
NGNan van Geloven
Nan van Geloven
JHJoost A. van Hilten
Joost A. van Hilten
RWRinie J. van Wordragen-Vlaswinkel
Rinie J. van Wordragen-Vlaswinkel
JKJean-Louis H. Kerkhoffs
Jean-Louis H. Kerkhoffs
Pathogen inactivation of platelet concentrates reduces the risk for blood-borne infections. However, its effect on platelet function and hemostatic efficacy of transfusion is unclear. We conducted a randomized noninferiority trial comparing the efficacy of pathogen-inactivated platelets using riboflavin and UV B illumination technology (intervention) compared with standard plasma-stored platelets (control) for the prevention of bleeding in patients with hematologic malignancies and thrombocytopenia. The primary outcome parameter was the proportion of transfusion-treatment periods in which the patient had grade 2 or higher bleeding, as defined by World Health Organization criteria. Between November 2010 and April 2016, 469 unique patients were randomized to 567 transfusion-treatment periods (283 in the control arm, 284 in the intervention arm). There was a 3% absolute difference in grade 2 or higher bleeding in the intention-to-treat analysis: 51% of the transfusion-treatment periods in the control arm and 54% in the intervention arm (95% confidence interval [CI], −6 to 11; P = .012 for noninferiority). However, in the per-protocol analysis, the difference in grade 2 or higher bleeding was 8%: 44% in the control arm and 52% in the intervention arm (95% CI −2 to 18; P = .19 for noninferiority). Transfusion increment parameters were ∼50% lower in the intervention arm. There was no difference in the proportion of patients developing HLA class I alloantibodies. In conclusion, the noninferiority criterion for pathogen-inactivated platelets was met in the intention-to-treat analysis. This finding was not demonstrated in the per-protocol analysis. This trial was registered at The Netherlands National Trial Registry as #NTR2106 and at www.clinicaltrials.gov as #NCT02783313. Publisher9s Note: There is a Blood Commentary on this article in this issue. Key Points Pathogen-inactivated platelets were noninferior in preventing bleeding only in intention-to-treat analysis. In contrast to animal models, alloimmunization could not be prevented when using pathogen-inactivated platelets. Visual Abstract

27 September 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
TOThijs L.J. van Osch
Thijs L.J. van Osch
TPTamas Pongracz
Tamas Pongracz
DGDionne M. Geerdes
Dionne M. Geerdes
JMJuk Yee Mok
Juk Yee Mok
WEWim J.E. van Esch
Wim J.E. van Esch
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
The formation of alloantibodies directed against class I human leukocyte antigens (HLA) continues to be a clinically challenging complication after platelet transfusions, which can lead to platelet refractoriness (PR) and occurs in approximately 5%–15% of patients with chronic platelet support. Interestingly, anti‐HLA IgG levels in alloimmunized patients do not seem to predict PR, suggesting functional or qualitative differences among anti‐HLA IgG. The binding of these alloantibodies to donor platelets can result in rapid clearance after transfusion, presumably via FcγR‐mediated phagocytosis and/or complement activation, which both are affected by the IgG‐Fc glycosylation. To characterize the Fc glycosylation profile of anti‐HLA class I antibodies formed after platelet transfusion and to investigate its effect on clinical outcome. We screened and captured anti‐HLA class I antibodies (anti‐HLA A2, anti‐HLA A24, and anti‐HLA B7) developed after platelet transfusions in hemato‐oncology patients, who were included in the PREPAReS Trial. Using liquid chromatography‐mass spectrometry, we analyzed the glycosylation profiles of total and anti‐HLA IgG1 developed over time. Subsequently, the glycosylation data was linked to the patients' clinical information and posttransfusion increments. The glycosylation profile of anti‐HLA antibodies was highly variable between patients. In general, Fc galactosylation and sialylation levels were elevated compared to total plasma IgG, which correlated negatively with the platelet count increment. Furthermore, high levels of afucosylation were observed for two patients. These differences in composition of anti‐HLA Fc‐glycosylation profiles could potentially explain the variation in clinical severity between patients.

10 May 2022 in American Journal of Hematology
Verified
Journal Article
Open access
AVAnnelies van Vuren
Annelies van Vuren
JKJean Louis Kerkhoffs
Jean Louis Kerkhoffs
SSSaskia Schols
Saskia Schols
ARAnita Rijneveld
Anita Rijneveld
ENErfan Nur
Erfan Nur
EBEduard J. van Beers
Eduard J. van Beers
Iron overload is a severe general complication of hereditary anemias. Treatment with iron chelators is hampered by important side‐effects, high costs, and the lack of availability in many countries with a high prevalence of hereditary anemias. In this phase III randomized placebo‐controlled trial, we assigned adults with non‐transfusion‐dependent hereditary anemias with mild‐to‐moderate iron overload to receive esomeprazole (at a dose of 40 mg twice daily) or placebo for 12 months in a cross‐over design. The primary end point was change of liver iron content measured by MRI. A total of 30 participants were enrolled in the trial. Treatment with esomeprazole resulted in a statistically significant reduction in liver iron content that was 0.55 mg Fe/g dw larger than after treatment with placebo (95%CI [0.05 to 1.06]; p = 0.03). Median baseline liver iron content at the start of esomeprazole was 4.99 versus 4.49 mg Fe/g dw at start of placebo. Mean delta liver iron content after esomeprazole treatment was −0.57 (SD 1.20) versus −0.11 mg Fe/g dw (SD 0.75) after placebo treatment. Esomeprazole was well tolerated, reported adverse events were mild and none of the patients withdrew from the study due to side effects. In summary, esomeprazole resulted in a significant reduction in liver iron content when compared to placebo in a heterogeneous group of patients with non‐transfusion‐dependent hereditary anemias. From an international perspective this result can have major implications given the fact that proton pump inhibitors may frequently be the only realistic therapy for many patients without access to or not tolerating iron chelators.

3 April 2020 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
PKPaul G. Kemps
Paul G. Kemps
ACArjen H. G. Cleven
Arjen H. G. Cleven
TWTom Van Wezel
Tom Van Wezel
RERonald van Eijk
Ronald van Eijk
FBFreek J. Bot
Freek J. Bot
JKJean‐Louis H. Kerkhoffs
Jean‐Louis H. Kerkhoffs
Click on the book chapter title to read more.

18 April 2024 in Transfusion
Verified
Journal Article
Closed access
THTamar Hubert
Tamar Hubert
JKJean Louis Kerkhoffs
Jean Louis Kerkhoffs
ABAnneke Brand
Anneke Brand
HSHenk Schonewille
Henk Schonewille

13 November 2019 in Blood
Verified
Journal Article
Open access
AVAnnelies J. Van Vuren
Annelies J. Van Vuren
BBBart J. Biemond
Bart J. Biemond
JKJean-Louis Kerkhoffs
Jean-Louis Kerkhoffs
SSSaskia Schols
Saskia Schols
ARA. W. Rijneveld
A. W. Rijneveld
EBEduard J. van Beers
Eduard J. van Beers
Background: Iron overload is an emerging and underestimated problem in management of patients with hereditary anemia characterized by chronic hemolysis or ineffective erythropoiesis in the absence of regular red cell transfusions. Liver iron overload was present in 65% of the patients with hereditary hemolytic anemia who were never transfused. (Van Straaten et al., Br J Haematol. 2018) Iron-loading results from inadequately high intestinal iron absorption in response to low hepcidin and ultimately leads to iron overload in liver and other organs. Iron chelation treatment is recommended, however drug-related toxicity is considerable, and treatment with iron chelators is expensive. Alternative treatment options for anemic patients not tolerating iron chelating agents are not available. For adequate iron absorption, a low luminal pH is required to solubilize dietary iron salts, and to promote the reduction of dietary Fe(III) to Fe(II) by ferriredutases as only Fe(II) can be absorbed. Proton pump inhibitors (PPI) block gastric acid secretion and thereby impede iron absorption. No studies are available that quantify effects of PPIs on dietary iron absorption in human. However, PPIs have shown to minimize phlebotomy requirements in patients with hereditary hemochromatosis. (Vanclooster et al., Gastroenterology. 2017) Here we report the design of the currently ongoing PPI SHINE AGAIN study that evaluates the efficacy and safety of PPI treatment in patients with non-transfusion dependent hereditary anemias. Methods: The PPI SHINE AGAIN is a phase 3, multicentre, randomized, placebo-controlled, cross-over clinical trial (Netherlands Trial Register, identifier [NL6659]). Transfusion independent adults with a form of hemolytic or dyserythropoietic anemia and mild to moderate iron overload are randomized in a 1:1 ratio to start with either esomeprazole 40 mg (administered orally BID) or placebo. Mild to moderate iron overload is defined as baseline liver iron content (LIC) of 3-15 mg Fe/g dry weight as measured by T2* MRI (MRQuantif Software Université de Rennes, https://imagemed.univ-rennes1.fr/en/mrquantif/quantif.php) without or on stable iron chelation therapy with no expected dose adjustments over the next 2 years. Additional criteria included baseline Hb ≤ 11.3 g/dL, expected to receive less than 4 red cell transfusions in the following 12 months, and no phlebotomies. The trial consists of two treatment periods of 12 months each (Figure), directly starting after baseline MRI. The primary study end-point is effectiveness of PPI treatment defined as difference in delta LIC after one-year treatment with esomeprazole compared to one-year treatment with placebo. Key secondary endpoints include tolerability, quality of life (assessed by EQ5D-5L questionnaire) and cost-effectiveness (assessed by iMTA Productivity Cost Questionnaire and iMTA Medical Consumption Questionnaire). Inclusion in the PPI SHINE AGAIN was completed in April 2019. Thirty patients are enrolled (non-transfusion dependent β-thalassemia n=10; pyruvate kinase deficiency n=8; congenital dyserythropoietic anemia n=3; sideroblastic anemia n=3; SCD n=2; HbH disease n=2; hereditary elliptocytosis n=1; G6PD deficiency n=1) with a median age of 44 years (IQR 28, 54). Results are expected Q3 2020. The trial is funded by ZonMW, The Netherlands Organization for Health and Research Development, and by the Innovatiefonds Zorgverzekeraars. Disclosures Nur: Novartis Pharmaceuticals: Consultancy. van Wijk:Agios Pharmaceuticals: Consultancy, Research Funding; RR Mechatronics: Research Funding. van Beers:Agios Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Research Funding; Pfizer: Research Funding; RR Mechatronics: Research Funding.